CASE COMMENT : UNILATERAL PRACTICES - FRENCH LAW - PREDATORY PRICING

Predatory pricing : The Paris Court of Appeal quashes Glaxo’s condemnation for having excluded a generic drug manufacturer from the hospital market (GlaxoSmithKline)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. CA Paris, 1st ch. H, April 8, 2008, Glaxo SmithKline Laboratoryv. Conc. conc., Dec. no. 07-D-09 of 14 March 2007 An additional episode is added to the already long saga of the Nouvelles Messageries de la presse parisienne (NMPP) (interim measures, appeal, two judgments of the Court of Cassation, V. notably A. Wachsmann, Infrastructures essentielles : Le logiciel Presse 2000 n'est pas une infrastructure essentielle (NMPP), Concurrences, N° 4-2005, pp. 77-79.Cass. com. 12 July 2005, note M. Malaurie-Vignal, Contrats Concurrence Consommation n° 11, November 2005, comm. 190; Communication Commerce électronique n° 10, October 2005, comm. 149, note

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Catholic University of Louvain

Quotation

Anne-Lise Sibony, Predatory pricing : The Paris Court of Appeal quashes Glaxo’s condemnation for having excluded a generic drug manufacturer from the hospital market (GlaxoSmithKline), 8 April 2008, Concurrences N° 2-2008, Art. N° 16566, p. 118

Visites 4676

All reviews